Health
Becton Dickinson Plans Life Sciences Segment Separation
- Company working with advisers as it seeks to boost stock price
- Becton could announce plans with its earnings this week
This article is for subscribers only.
Medical device maker Becton Dickinson & Co. is considering a potential separation of its life sciences segment, which could be valued at about $30 billion, according to people familiar with the matter.
Becton is working with advisers to study a possible separation of the division as it seeks to boost its stock price, the people said, asking not to be identified because the information is confidential.